Zenith Epigenetics Ltd. ("Zenith Epigenetics") is a clinical stage biotechnology company developing best in class bromodomain and extraterminal domain protein (BET) inhibitors for the treatment of cancer and other disorders with significant unmet medical need. Our cutting edge epigenetic platform of innovative biology and chemistry has generated differentiated, potent and selective BET inhibitors. Our goal is to be a leading epigenetic company translating bromodomain biology into impactful therapies.
Our lead BET inhibitor (BETi), ZEN-3694, is in Phase 2 clinical development for the treatment of metastatic castration resistant prostate cancer (mCRPC) and in a Phase 1b/2 clinical trial, in collaboration with Pfizer, for triple negative breast cancer (TNBC) with first patient dosing achieved in June of 2019.
Our strong management team and organization allow us to efficiently develop BETi combination therapies for multiple indications. Our research team, based in Calgary, Alberta, with its broad and longstanding experience in epigenetics, is a leader in the discovery of pan and selective BET inhibitors in oncology and other indications. The development activities are led by our San Francisco based team where a strong emphasis on translational medicine, to drive patient pre-selection, combined with a proven track record in drug development allows us to excel in the field of epigenetics.
Zenith Epigenetics is a wholly-owned subsidiary of Zenith Capital Corp.